This study is testing a new immunotherapy called E7 TCR-T cells for people with certain HPV-associated cancers that have spread or come back. These cancers include cervical, throat, oropharynx, anal, and vulva cancers. You would receive a conditioning treatment (cyclophosphamide and fludarabine), a single infusion of E7 TCR-T cells, and then a medication called aldesleukin. Researchers want to see how well the treatment shrinks tumors. To join, your cancer must be linked to HPV-16, and you must be at least 18 years old. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.

What's involved

Participants will receive a conditioning regimen, a single intravenous infusion of E7 TCR-T cells, and up to six doses of aldesleukin.

Compensation

Not stated in the trial record.

Follow-up

Tumor response will be measured at 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.